Popular
WVE · Medicine & biotech · U.S.

Wave Life Sciences

Develops RNA medicines for obesity and rare genetic diseases.

Company Health

50
/100
Mixed
A quick check of the business from its yearly reports (2022–2025). It doesn’t say whether the stock is a good buy.
Does it make money?
0 of 25 · Poor
It lost money last year: $478 of every $100 in sales.
Is it growing?
25 of 25 · Good
Sales grew about 127% a year over the last 3 years.
Can it handle what it owes?
25 of 25 · Good
It holds more cash than everything it owes.
Does it bring in spare cash?
0 of 25 · Poor
It spent more cash than it brought in: $440 of every $100 in sales.

Who owns it

1 of 23 own it · Nobody changed their stake
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Himalaya Capital, Greenlight, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Wave Life Sciences’ yearly reports. Tap a year to see its figures.

Sales and profit

Sales grew from $20.1 million in 2020 to $42.7 million in 2025, and it lost money every year.
2025
Sales
$42.7 million
Loss
$204 million

Spare cash each year

It spent more cash than it brought in every year: $188 million more in 2025.
2025
Cash shortfall
$188 million
Spare cash is the cash its business brought in, minus what it spent on buildings and equipment.

What it owns and what it owes

At the end of 2025 it owned $638 million, including $602 million in cash, and owed $112 million.

Key facts

From its yearly report for 2025.
Sales
$42.7 million
Loss
$204 million
Cash shortfall
$188 million
Cash in the bank
$602 million
Everything it owes
$112 million
Year ends
December
Money shown in
U.S. dollars
Latest yearly report
10-K/A, filed Apr 30, 2026
Figures from Wave Life Sciences’ yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy